News | February 19, 2022
Natco Q3FY22 PAT up 27% to Rs 80 Cr
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The new centre will comprise a team of 50 highly experienced specialists
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The hospital has recently launched Radionuclide therapy
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
Subscribe To Our Newsletter & Stay Updated
